Patients with meibomian gland disease who are looking for a more long-lasting treatment than that of topical products are amenable to various in-office procedures, including the application of intense pulsed light (IPL) to reduce inflammation and aid expression of clogged glands. A new IPL device from Lumenis, called OptiLight, was recently cleared by the FDA and will make its way to market soon.

A company press release says the device significantly improved tear breakup time, meibum quality and gland expressibility in a randomized controlled trial. OptiLight includes what Lumenis calls optimal pulse technology, which it says gives users the ability to control the pulse shape, provides reproducible results and creates gentler, more comfortable treatments.

The product’s formal launch will take place on May 13. For more information, visit www.lumenis.com/optilight.